The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic Dyslipidemia

The Effectiveness and Safety of Fenofibrate and Saroglitazar in the Treatment of Diabetic Dyslipidemia

Objective: This study aimed to evaluate the efficacy and safety of saroglitazar and fenofibrate in treating diabetic dyslipidemia. Study Design: Comparative cross-sectional study. Place and Duration of Study: The study was conducted at the Department of Biochemistry, Nishtar Medical University and H...

Full description

Saved in:

Bibliographic Details
Main Authors:	Bakhtawar Farooq, Rafay-Ur-Rehman Cheema, Zahid Habib Qureshi, Nabeela Yasmeen, Ejaz Hussain Sahu
Format:	Article
Language:	English
Published:	National University of Medical Sciences 2024-05-01
Series:	Life and Science
Subjects:	atorvastatin, diabetes mellitus, dyslipidemias, fenofibrate, triglyceride
Online Access:	https://ojs.lifenscience.org/index.php/life-and-science/article/view/632
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and Safety of the Fixed-Dose Combination of Atorvastatin/Fenofibrate Versus Atorvastatin on the Lipid Profile of Patients with Type 2 Diabetes and Dyslipidemia
by: Francisco G. Padilla-Padilla, et al.
Published: (2025-05-01)

Beneficial Effect of Fenofibrate in Combination with Silymarin on Parameters of Hereditary Hypertriglyceridemia-Induced Disorders in an Animal Model of Metabolic Syndrome
by: Jan Soukop, et al.
Published: (2025-01-01)

Atorvastatin effectiveness in dyslipidemia correction among coronary heart disease and arterial hypertension patients with high risk of cardiovascular complications
by: E. V. Minakov, et al.
Published: (2007-10-01)

Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy
by: Olga Nikolaevna Tkacheva, et al.
Published: (2010-03-01)

EFFECTS OF ATORVASTATIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DYSLIPIDEMIA
by: N. M. Nikitina, et al.
Published: (2014-07-01)

Cost-effectiveness of fenofibrate for preventing diabetic complications in Australia
by: Hansoo Kim, et al.
Published: (2024-11-01)

Fenofibrate in Metabolic Dysfunction-associated Steatotic Liver Disease: A Systematic Review and Meta-analysis
by: Manoj Kumar, et al.
Published: (2025-05-01)

Pleiotropic effects of fenofibrate: focus on type 2 diabetes mellitus
by: Alexander Sergeevich Ametov, et al.
Published: (2014-12-01)

USING A COMBINATION OF PERINDOPRIL, INDAPAMIDE AND ROSUVASTATIN IN THE TREATMENT OF PATIENTS WITH HYPERTENSION AND DYSLIPIDEMIA
by: O. M. Drapkina, et al.
Published: (2017-09-01)

Dyslipidemia correction with atorvastatin in patients with coronary heart disease and arterial hypertension
by: N. B. Amirov, et al.
Published: (1970-01-01)

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA’s adverse event reporting system database
by: Qun Li, et al.
Published: (2025-02-01)

Review and analysis of 2023 Clinical Guidelines for Lipid Metabolism Disorders
by: I. V. Sergienko, et al.
Published: (2023-12-01)

Scale-up and optimization of fenofibrate-loaded fibers electrospun by corona-electrospinning
by: E. Bitay, et al.
Published: (2021-04-01)

Neuroprotective Effect of Leaf Extract of Moringa Oleifera And Fenofibrate on Learning and Memory in Wistar Rats Subjected to Water Immersion Restraint Stress
by: Stephen, Olawale Ajayi, et al.
Published: (2023)

Changes in Oral and Salivary Contents in Patients with Chronic Kidney Disease
by: Bakhtawar Farooq, et al.
Published: (2025-01-01)

Fenofibrate treatment during withdrawal reverses symptoms of ethanol-induced depression in male rats
by: Marcelo León, et al.
Published: (2025-08-01)

Clinical features and pathological changes in adult IgA nephropathy with dyslipidemia
by: LIU Rui, et al.
Published: (2019-01-01)

Saroglitazar suppresses KIM-1 and type IV collagen in high fat diet and low-dose streptozotocin-induced diabetic nephropathy in Wistar rats
by: Rizwan Ahamad, et al.
Published: (2024-11-01)

Intrahepatic cholestasis of pregnancy and maternal dyslipidemia: a systematic review and meta‐analysis
by: Yongchi Zhan, et al.
Published: (2022-07-01)

EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS, RUSSIA) GUIDELINES FOR THE DIAGNOSIS AND CORRECTION OF DYSLIPIDEMIA FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS (2020)
by: V. V. Kukharchuk, et al.
Published: (2020-06-01)

Associations Between the Polymorphisms in the Coding Sequence of SLCO1B1 and Blood Lipid Levels Before and After Treatment by Atorvastatin in the Chinese Han Adults with Dyslipidemia
by: Chen C, et al.
Published: (2024-12-01)

Effect of adding fenofibrate versus curcumin to glimepiride in patients with type 2 diabetes: a randomized controlled trial
by: Eman M. Nada, et al.
Published: (2025-06-01)

ABNORMAL BLOOD LIPIDS LEVELS (DYSLIPIDEMIA) TREATMENT WITH ACUPUNCTURE METHOD
by: Anissa Maulina Rinjani, et al.
Published: (2022-03-01)

Long-term low-dose atorvastatin therapy and prevention of macroangiopathy complications in elderly patients with Type 2 diabetes mellitus
by: G. A. Batrak, et al.
Published: (2010-06-01)

Correlation between Systolic Blood Pressure and Triglyceride Level in the Uzbekistan Population
by: Bu Yong Kim, et al.
Published: (2021-01-01)

Association between dyslipidemia and vitamin D deficiency: a cross-sectional study in Chinese healthy population
by: Bin Li, et al.
Published: (2025-04-01)

Analysis of the association between long-term exposure to low-dose ionizing radiation and dyslipidemia and its components in medical radiologists: The mediating role of inflammatory markers
by: Changyong Wen, et al.
Published: (2025-06-01)

Randomized «FARVATER» study. Atorvastatin (10 and 20 mg/d) in treating patients with coronary heart disease and dyslipidemia: effects on lipids, C-reactive protein and fibrinogen levels
by: A. V. Susekov, et al.
Published: (2006-12-01)

Eurasian Association of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS) Guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2025)
by: M. V. Ezhov, et al.
Published: (2025-06-01)

Helicobacter pylori infection increases the risk of dyslipidemia in Chinese non-obese and non-diabetic population from the perspective of age category: a retrospective cross-sectional study
by: Huihui Shang, et al.
Published: (2025-07-01)

SPECIFICS OF LIPID METABOLISM AND ATORVASTATIN EFFICACY IN TYPE 2 DIABETES WITH CARRIAGE OF VARIOUS POLYMORPHISMS OF CHOLESTEROL ETHER CARRYING PROTEIN TaqIB GENE
by: M. V. Kim, et al.
Published: (2015-10-01)

Dyslipidemia in the Russian Federation: population data, associations with risk factors
by: O. M. Drapkina, et al.
Published: (2023-12-01)

Randomized study FARVATER: Part II. Atorvastatin effects on endothelial function, vascular wall distensibility and stiffness
by: A. V. Susekov, et al.
Published: (2007-06-01)

DYSLIPIDEMIA FEATURES IN CHILDREN
by: T. I. Turkinа, et al.
Published: (2016-01-01)

Magnitude of dyslipidemia in type 2 diabetes
by: Chanchal Das, et al.
Published: (2022-05-01)

Fiber in the Treatment of Dyslipidemia in Pediatric Patients
by: Maria Elena Capra, et al.
Published: (2025-03-01)

THE EFFECT OF STRATIFIED DOSES OF CURRY LEAF EXTRACT (MURRAYA KOENIGII) ON TOTAL CHOLESTEROL AND TRIGLYCERIDES IN MALE SPRAGUE-DAWLEY RATS INDUCED BY HIGH FAT FEED
by: Muhammad Iqbal Reynaldi, et al.
Published: (2021-01-01)

Serum lipid profile abnormalities among beta-thalassemia patients: a systematic review and meta-analysis
by: Sagad O. O. Mohamed, et al.
Published: (2024-11-01)

Comparative study of lipid profile among type 2 diabetics on treatment within Owo, metropolis, Nigeria.
by: Olaniyan, O.O., Adebayo T.O., Onyiba G.A., Atere A.D., Obot A.S., Ajayi A.A., Adedokun A.A., Shoyinka S.D., Yekeen S.B., and Abidoye O.J.
Published: (2024-01-01)

Beetroot (Beta vulgaris L.) reduces cholesterol and triglyceride in dyslipidemic male rats sprague–dawley model
by: Yulia Rohman, et al.
Published: (2024-06-01)